Watanabe F D, Mullon C J, Hewitt W R, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg, 1997, 225: 484-491
[2]
Xue Y L, Zhao S F, Luo Y, et al. TECA hybrid artificial liver support system in treatment of acute liver failure. World J Gastroenterol,2001, 7: 826-829
[3]
Mazariegos G V, Kramer D J, Lopez R C, et al. Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients. ASAIO J, 2001, 47: 471-475
[4]
Morsiani E, Pazzi P, Puviani A C, et al. Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients. Int J Artif Organs, 2002, 25: 192-202
[5]
Mundt A, Puhl G, Muller A, et al. A method to assess biochemical activity of liver cells during clinical application of extracorporeal hybrid liver support. Int J Artif Organs, 2002, 25: 542-548
[6]
Donini A, Baccarani U, Risaliti A, et al. Temporary neurological improvement in a patient with acute or chronic liver failure treated with a bioartificial liver device. Am J Gastroenterol, 2000, 95: 1102-1104
[7]
van de Kerkhove M P, Di Florio E, Scuderi V, et al. Phase I clinical trial with the AMC-bioartificial liver. Int J Artif Organs, 2002, 25:950-959
[8]
Kjaergard L L, Liu J, Als-Nielsen B, et al. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: A systematic review. J Am Med Assoc, 2003, 289: 217-222
[9]
Kawazoe Y, Eguchi S, Sugiyama N, et al. Comparison between bioartificial and artificial liver for the treatment of acute liver failure in pigs. World J Gastroenterol, 2006, 12: 7503-7507
[10]
Iwata H, Ueda Y. Pharmacokinetic considerations in development of a bioartificial liver. Clin Pharmacokinet, 2004, 43: 211-225
[11]
Park J K, Lee D H. Bioartificial liver systems: Current status and future perspective. J Biosci Bioeng, 2005, 99: 311-319
[12]
van Wezel A L. Growth of cell-strains and primary cells on micro-carriers in homogeneous culture. Nature, 1967, 216: 64-65
[13]
Gao Y, Xu X P, Hu H Z, et al. Cultivation of human liver cell lines with microcarriers acting as biological materials of bioartificial liver. World J Gastroenterol, 1999, 5: 221-224
Kobayashi N, Okitsu T, Maruyama M, et al. Development of a cellulose-based microcarrier containing cellular adhesive peptides for a bioartificial liver. Transplant Proc, 2003, 35: 443-444
[16]
Pazzi P, Morsiani E, Vilei M T, et al. Serum bile acids in patients with liver failure supported with a bioartificial liver. Aliment Pharmacol Ther, 2002, 16: 1547-1554
[17]
Schrem H, Kleine M, Borlak J, et al. Physiological incompatibilities of porcine hepatocytes for clinical liver support. Liver Transpl, 2006,12: 1832-1840
[18]
Li K, Wang Y, Miao Z, et al. Chitosan/gelatin composite microcarrier for hepatocyte culture. Biotechnol Lett, 2004, 26: 879-883
[19]
Xu T, Li S L, Yu Y T. Preparation and culture of hepatocyte on gelatin microcarriers. J Biomed Mater Res A, 2003, 65: 306-310
[20]
Ding S, Cui Y L, Dong T J, et al. Preparation and characterization of chitosan-gelatin composite microcarrier crosslinked by genipin. In: Proceedings of 2010 International Conference of Natural Product and Traditional Medicine, 2010, Aug 21-23, Xi’an. Xi’an: Northwest University Press, 2010. 147-151
[21]
Bernuau J, Rueff B, Benhamou J P. Fulminant and subfulminant liver failure: Definitions and causes. Semin Liver Dis, 1986, 6: 97-106
[22]
van de Kerkhove M P, Hoekstra R, Chamuleau R A, et al. Clinical application of bioartificial liver support systems. Ann Surg, 2004, 240:216-230
[23]
Ellis A J, Hughes R D, Wendon J A, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology,1996, 24: 1446-1451
[24]
Xu A S, Reid L M. Soft, porous poly(D,L-lactide-co-glycotide) microcarriers designed for ex vivo studies and for transplantation of adherent cell types including progenitors. Ann NY Acad Sci, 2001, 944: 144-159
[25]
Werner A, Duvar S, Muthing J, et al. Cultivation of immortalized human hepatocytes HepZ on macroporous CultiSpher G microcarriers. Biotechnol Bioeng, 2000, 68: 59-70
[26]
Xu Q, Yu D, Qiu Y, et al. Function of a new internal bioartificial liver: An in vitro study. Ann Clin Lab Sci, 2003, 33: 306-312
[27]
Suh K S, Lilja H, Kamohara Y, et al. Bioartificial liver treatment in rats with fulminant hepatic failure: Effect on DNA-binding activity of liver-enriched and growth-associated transcription factors. J Surg Res, 1999, 85: 243-250
[28]
Naruse K, Tang W, Makuuch M. Artificial and bioartificial liver support: A review of perfusion treatment for hepatic failure patients. World J Gastroenterol, 2007, 13: 1516-1521
[29]
Iwahori T, Matsuno N, Johjima Y, et al. Radial flow bioreactor for the creation of bioartificial liver and kidney. Transplant Proc, 2005, 37:212-214
[30]
Sussman N L, Gislason G T, Conlin C A, et al. The Hepatix extracorporeal liver assist device: Initial clinical experience. Artif Organs,1994, 18: 390-396
De Bartolo L, Salerno S, Curcio E, et al. Human hepatocyte functions in a crossed hollow fiber membrane bioreactor. Biomaterials, 2009,30: 2531-2543
[33]
Gao Y, Mu N, Xu X P, et al. Porcine acute liver failure model established by two-phase surgery and treated with hollow fiber bioartificial liver support system. World J Gastroenterol, 2005, 11: 5468-5474
[34]
Morsiani E, Pazzi P, Moscioni A D, et al. In vitro morphological and functional characterization of isolated porcine hepatocytes for extracorporeal liver support: Bile acid uptake and conjugation. J Surg Res, 1998, 79: 54-60
[35]
Chamuleau R A, Poyck P P, van de Kerkhove M P. Bioartificial liver: Its pros and cons. Ther Apher Dial, 2006, 10: 168-174
[36]
Jauregui H O, Naik S, Santangini H A, et al. The use of microcarrier-roller bottle culture for large-scale production of porcine hepatocytes. Tissue Eng, 1997, 3: 17-25
[37]
Donato M T, Castell J V, Gomez-Lechon M J. Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices: Comparison with other hepatic cellular models. J Hepatol, 1999, 31: 542-549
[38]
Ehashi T, Ohshima N, Miyoshi H. Three-dimensional culture of porcine fetal liver cells for a bioartificial liver. J Biomed Mater Res A,2006, 77: 90-96
[39]
Kawashita Y, Ohtsuru A, Fujioka H, et al. Safe and efficient gene transfer into porcine hepatocytes using Sendai virus-cationic liposomes for bioartificial liver support. Artif Organs, 2000, 24: 932-938
[40]
Sharma R, Greenhough S, Medine C N, et al. Three-dimensional culture of human embryonic stem cell derived hepatic endoderm and its role in bioartificial liver construction. J Biomed Biotechnol, 2010, 2010: 236147
[41]
Kobayashi N. Life support of artificial liver: Development of a bioartificial liver to treat liver failure. J Hepatobiliary Pancreat Surg, 2009,16: 113-117
[42]
Omasa T, Kim K, Hiramatsu S, et al. Construction and evaluation of drug-metabolizing cell line for bioartificial liver support system. Biotechnol Prog, 2005, 21: 161-167
[43]
Wen F, Chang S, Toh Y C, et al. Development of dual-compartment perfusion bioreactor for serial coculture of hepatocytes and stellate cells in poly(lactic-co-glycolic acid)-collagen scaffolds. J Biomed Mater Res B Appl Biomater, 2008, 87: 154-162
[44]
Chamuleau R A, Deurholt T, Hoekstra R. Which are the right cells to be used in a bioartificial liver[J].Metab Brain Dis.2005, 20:327-335
[45]
Chiono V, Pulieri E, Vozzi G, et al. Genipin-crosslinked chitosan/gelatin blends for biomedical applications. J Mater Sci Mater Med, 2008,19: 889-898
[46]
Strain A J, Neuberger J M. A bioartificial liver—State of the art. Science, 2002, 295: 1005-1009
